real-world safety data of rituximab among mexican patients with neuromyelitis optica spectrum disorders

被引：0
作者：
Thomas, Domingo Coutinho [1 ]
Lopez, Yazmin Martinez [1 ]
Villanueva, Homero Alcocer [1 ]
Lopez, Sarai Rivera [1 ]
Gonzalez, Jose Gonzalez [1 ]
Vazquez, Teresita Corona [1 ]
Rivas, Veronica [1 ]
Rivera, Jose De Jesus Flores [1 ]
机构：
[1] Natl Inst Neurol & Neurosurg, Neurol Dept Demyelinating Disorders Clin, Mexico City, Mexico
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1680/3027
引用
收藏
页码：1127 / 1127
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Rituximab in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : NP12 - NP13
  • [32] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Ongphichetmetha, Tatchaporn
    Jitprapaikulsan, Jiraporn
    Siritho, Sasitorn
    Rattanathamsakul, Natthapon
    Detweeratham, Thammachet
    Prayoonwiwat, Naraporn
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [33] Real World-Evidence: Efficacy data of Rituximab in patients with Neuromyelitis Optica Spectrum AQP4-IgG serum-positive patients
    Coutinho Thomas, Domingo
    Gonzalez Perez, Karla
    Evangelista Osorio, Arath Amauri
    Martinez Lopez, Yazmin
    Rivas, Veronica
    Corona Vazquez, Teresita
    Flores Rivera, Jose De Jesus
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1082 - 1082
  • [34] A Real-World Analysis of Relapses and Costs of Neuromyelitis Optica Spectrum Disorders Using a United States Administrative Claims Database
    Stafkey-Mailey, Dana
    Boscoe, Audra
    Ajmera, Mayank
    Mauskopf, Josephine
    Iloeje, Uchenna
    Levy, Michael
    NEUROLOGY, 2016, 86
  • [35] Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
    Tatchaporn Ongphichetmetha
    Jiraporn Jitprapaikulsan
    Sasitorn Siritho
    Natthapon Rattanathamsakul
    Thammachet Detweeratham
    Naraporn Prayoonwiwat
    Scientific Reports, 14
  • [36] Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders A Systematic Review and Meta-analysis
    Damato, Valentina
    Evoli, Amelia
    Iorio, Raffaele
    JAMA NEUROLOGY, 2016, 73 (11) : 1342 - 1348
  • [37] Patients with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder: Turkish Multicenter Data
    Altintas, A.
    Karabudak, R.
    Balci, B. Petek
    Terzi, M.
    Soysal, A.
    Saip, S.
    Kurne, A. Tuncer
    Uygunoglu, U.
    Nalbantoglu, M.
    Gozubatik-Celik, G.
    Isik, N.
    Celik, Y.
    Gokcay, F.
    Duman, T.
    Boz, C.
    Yucesan, C.
    Celebisoy, N.
    Diker, S.
    Isikay, I. C.
    Kansu, T.
    Siva, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 824 - 825
  • [38] Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders
    Correa-Diaz, Edgar Patricio
    Torres-Herran, Germaine Eleanor
    Zambrano, Joselyn Elizabeth Mino
    Paredes-Gonzalez, Victor
    Caiza-Zambrano, Francisco Jose
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [39] Azathioprine for first-line treatment in neuromyelitis optica and neuromyelitis optica spectrum disorders: efficacy and safety
    Kim, J. H.
    Park, M. S.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 91 - 91
  • [40] Psychiatric comorbidities and suicidality among patients with neuromyelitis optica spectrum disorders in Argentina
    Fernandez, V. C.
    Alonso, N.
    Melamud, L.
    Villa, A. M.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 19 : 40 - 43
12345